10x Genomics (TXG) Competitors

$27.52
-0.06 (-0.22%)
(As of 04/24/2024 ET)

TXG vs. OLK, EYPT, BIO, BIO.B, BRKR, RVTY, CBAY, BHVN, SEM, and RARE

Should you be buying 10x Genomics stock or one of its competitors? The main competitors of 10x Genomics include Olink Holding AB (publ) (OLK), EyePoint Pharmaceuticals (EYPT), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), Bruker (BRKR), Revvity (RVTY), CymaBay Therapeutics (CBAY), Biohaven (BHVN), Select Medical (SEM), and Ultragenyx Pharmaceutical (RARE).

10x Genomics vs.

10x Genomics (NASDAQ:TXG) and Olink Holding AB (publ) (NASDAQ:OLK) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Olink Holding AB (publ) has a net margin of -18.63% compared to 10x Genomics' net margin of -41.17%. Olink Holding AB (publ)'s return on equity of -6.50% beat 10x Genomics' return on equity.

Company Net Margins Return on Equity Return on Assets
10x Genomics-41.17% -28.82% -22.67%
Olink Holding AB (publ) -18.63%-6.50%-5.63%

10x Genomics received 27 more outperform votes than Olink Holding AB (publ) when rated by MarketBeat users. Likewise, 54.17% of users gave 10x Genomics an outperform vote while only 34.29% of users gave Olink Holding AB (publ) an outperform vote.

CompanyUnderperformOutperform
10x GenomicsOutperform Votes
39
54.17%
Underperform Votes
33
45.83%
Olink Holding AB (publ)Outperform Votes
12
34.29%
Underperform Votes
23
65.71%

10x Genomics presently has a consensus target price of $60.22, indicating a potential upside of 121.08%. Olink Holding AB (publ) has a consensus target price of $26.00, indicating a potential upside of 15.40%. Given 10x Genomics' stronger consensus rating and higher possible upside, equities analysts clearly believe 10x Genomics is more favorable than Olink Holding AB (publ).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
10x Genomics
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89
Olink Holding AB (publ)
0 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 30.2% of Olink Holding AB (publ) shares are held by institutional investors. 10.7% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

10x Genomics has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500. Comparatively, Olink Holding AB (publ) has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.

Olink Holding AB (publ) has lower revenue, but higher earnings than 10x Genomics. Olink Holding AB (publ) is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
10x Genomics$618.73M5.25-$255.10M-$2.17-12.56
Olink Holding AB (publ)$169.60M16.52-$31.60M-$0.25-90.12

In the previous week, 10x Genomics had 6 more articles in the media than Olink Holding AB (publ). MarketBeat recorded 7 mentions for 10x Genomics and 1 mentions for Olink Holding AB (publ). 10x Genomics' average media sentiment score of 0.28 beat Olink Holding AB (publ)'s score of 0.00 indicating that 10x Genomics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
10x Genomics
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Olink Holding AB (publ)
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

10x Genomics beats Olink Holding AB (publ) on 12 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TXG vs. The Competition

Metric10x GenomicsAnalytical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$3.25B$5.37B$4.82B$7.47B
Dividend YieldN/A0.41%5.47%3.96%
P/E Ratio-12.568.21185.8116.66
Price / Sales5.255.112,314.8480.58
Price / CashN/A36.9045.6834.56
Price / Book4.383.534.644.28
Net Income-$255.10M-$9.41M$102.53M$213.77M
7 Day Performance-6.55%-2.72%-0.21%0.96%
1 Month Performance-24.91%-12.28%-6.33%-4.43%
1 Year Performance-49.79%-27.77%9.38%7.54%

10x Genomics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OLK
Olink Holding AB (publ)
0.5729 of 5 stars
$22.66
-0.4%
$26.00
+14.7%
+1.3%$2.82B$169.60M-90.64707
EYPT
EyePoint Pharmaceuticals
2.4578 of 5 stars
$21.84
+2.6%
$33.86
+55.0%
+95.2%$1.09B$46.02M-11.93121Upcoming Earnings
Insider Buying
News Coverage
Positive News
BIO
Bio-Rad Laboratories
4.692 of 5 stars
$292.85
-2.5%
$468.00
+59.8%
-38.9%$8.35B$2.67B-13.638,030
BIO.B
Bio-Rad Laboratories
0 of 5 stars
$338.55
flat
N/AN/A$9.66B$2.67B-15.757,900
BRKR
Bruker
4.8543 of 5 stars
$83.89
-2.2%
$84.86
+1.2%
+1.3%$11.55B$2.96B28.739,707
RVTY
Revvity
3.9532 of 5 stars
$100.30
-2.0%
$118.91
+18.6%
N/A$12.39B$2.75B18.2411,500Upcoming Earnings
Positive News
CBAY
CymaBay Therapeutics
0.9291 of 5 stars
$32.48
flat
$28.65
-11.8%
+214.1%$3.73B$31.07M-33.48101
BHVN
Biohaven
3.6703 of 5 stars
$43.64
-2.5%
$52.00
+19.2%
+176.2%$3.56B$462.51M-7.71239Analyst Report
Insider Buying
News Coverage
SEM
Select Medical
4.7185 of 5 stars
$27.30
-1.1%
$34.40
+26.0%
-2.9%$3.50B$6.66B14.2954,600
RARE
Ultragenyx Pharmaceutical
4.4295 of 5 stars
$42.31
-1.3%
$91.55
+116.4%
+6.8%$3.48B$434.25M-5.081,276Analyst Report

Related Companies and Tools

This page (NASDAQ:TXG) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners